Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals announced that the FDA has approved TRYNGOLZA (olezarsen) as the first and only treatment indicated to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG, triglycerides ≥500 mg/dL). The drug is given as a 50 mg or 80 mg once-monthly self-administered autoinjector.
The approval is based on Phase 3 CORE and CORE2 data, where TRYNGOLZA lowered fasting triglycerides by up to 72% versus placebo at six months and sustained reductions at 12 months, reduced acute pancreatitis events by up to 91%, and saw 86% of patients with baseline and 12‑month data reach triglyceride levels below 500 mg/dL. The number needed to treat over one year to prevent one acute pancreatitis episode was 20 in the overall cohort and four in the highest‑risk subgroup. TRYNGOLZA will be available for sHTG in the U.S. in July and represents Ionis’ first independent commercial launch in a prevalent condition.
Ionis Pharmaceuticals EVP and Chief Development Officer Holly B. Kordasiewicz reported an exercise-and-sell transaction in Ionis common stock. On June 12, 2026, she sold a total of 60,846 shares in open-market sales, including 19,842 shares at a weighted average price of $74.0503 per share and 41,004 shares at a weighted average price of $73.0934 per share.
The sales were made under a pre-arranged Rule 10b5-1 Trading Plan adopted on March 13, 2026, meaning the trades were scheduled in advance. On the same date, she exercised non-qualified stock options covering a total of 60,846 shares of common stock at exercise prices of $32.60, $56.78, and $60.89 per share, converting derivative awards into shares that were then largely sold for liquidity.
IONIS PHARMACEUTICALS INC director Spencer R. Berthelsen exercised stock options and sold shares on the same day. He exercised non-qualified stock options covering 8,000 shares of Common Stock at an exercise price of $24.42 per share and then sold 8,000 shares in an open-market transaction at $73.49 per share pursuant to a Rule 10b5-1 Trading Plan adopted on September 12, 2025. After these transactions, he directly owned 156,013 shares of Common Stock. The filing also notes 70 shares of Common Stock held by his daughter, for which he disclaims beneficial ownership.
Reported proposed sale of 8,000 shares by an insider via stock option exercise. The filing shows a stock option exercise to sell 8,000 shares with a transaction date of 06/15/2026. A prior sale listed 8,000 shares on 06/01/2026 for $605,360.00.
IONS submitted a Form 144 notifying a proposed sale of Common Stock. The notice lists equity compensation option-exercise lots of 28,951, 19,895, and 12,000 shares and shows a filing/notice date of 06/12/2026 on Nasdaq.
Ionis Pharmaceuticals reported new clinical data for its experimental drug olezarsen in people with severe hypertriglyceridemia, a condition marked by very high blood fats. The company shared what it described as positive results from an ongoing extension of its CORE and CORE2 studies at a major lipid conference in Chicago.
The update focused on liver fat measurements using MRI technology in 53 patients who completed 12 months of treatment in the CORE open-label extension, all on an 80 mg dose of olezarsen. These patients represented about 25% of those enrolled in a dedicated liver fat substudy, which tracks hepatic fat fraction over time.
Ionis Pharmaceuticals director Peter N. Reikes received a grant of non-qualified stock options covering 10,753 shares of common stock. The options have an exercise price of $75.13 per share and were awarded under the company’s Amended & Restated 2002 Non-Employee Directors' Stock Option Plan.
The grant vests in three equal annual installments, with the first tranche vesting and becoming exercisable on June 4, 2027, and the options becoming fully vested and exercisable on June 4, 2029. The options expire on June 4, 2036. This is a compensation-related award rather than an open-market purchase or sale.
Ionis Pharmaceuticals director Ludwig Hantson received a grant of non-qualified stock options covering 10,753 shares of common stock at an exercise price of $75.13 per share. The options were granted at no cost as director compensation, vesting in three equal annual installments starting on June 4, 2027, and will be fully vested by June 4, 2029. The options expire on June 4, 2036, and were not exercisable as of the grant date.
IONIS PHARMACEUTICALS INC filed an initial Form 3 for Peter N. Reikes, who is identified as a director of the company and not a ten percent owner or officer. The filing reports no transactions or holdings data, serving as a baseline statement of beneficial ownership.
IONIS PHARMACEUTICALS INC director Ludwig Hantson filed an initial Form 3, which is a mandatory statement of beneficial ownership for insiders. This filing establishes his status as a director-level insider of the company but does not report any stock transactions or specific holdings.